We treated the CML and non-CML CD34+ cells using three different regimens in vitro to mimic potential clinical scenarios when used in combination with IM: GO or GO + 2μM IM for 72 h treatment (GO72); 72 h IM or NDC followed by 72 h GO treatment (GOIMGO); or, 72 h GO followed by 72 h IM or NDC (GOGOIM). The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.